Esoferr

Indonesia • Ferron Par Pharmaceuticals

Indication

Esomeprazole injection is indicated for gastric antisecretory treatment when the oral route is not possible, such as:

  • Gastroesophageal reflux disease in patients with esophagitis and/or severe symptoms of reflux.
  • Healing of gastric ulcers associated with NSAIDs therapy.
  • Short-term maintenance of hemostasis and prevention of rebleeding in patients following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.

Composition

Esomeprazole 40 mg

Package

1 vial of 40 mg

Dosage Forms

Injection

ATC Classification

A02A

Warning

Alcohol
Consult Your Doctor
Safety of this item for use with alcohol has not been established. Please consult your doctor.
Machinery
Caution
This item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.
Pregnancy
Caution
This item may not be safe for use during pregnancy. Use with caution and after consultation with your doctor.
Lactation
Not Recommended
This item is not safe for use during lactation.

Dosage

0 to 18 Years Old

Esomeprazole IV should not be used in children and adolescent since no data is available.

18 Years Old and Above

Gastric antisecretory treatment when the oral route is not possible:
Patients who cannot take oral medicines may be treated parenterally with 20-40 mg once daily. Patients with reflux esophagitis should be treated with 40 mg once daily. Patients with symptomatically for reflux disease should be treated with 20 mg once daily. For healing of gastric ulcers associated with NSAID therapy the usual dose is 20 mg once daily. Usually the IV treatment durations short and transfer to oral treatment should be made as soon as possible.

Maintenance of hemostasis and prevention of rebleeding of gastric and duodenal ulcers following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers:
80 mg should be administered as a bolus infusion over 30 minutes, followed by continuous intravenous infusion of 8 mg/hour given over 3 days (72 hours). The parenteral treatment period should be followed by acid-suppression therapy with esomeprazole 40 mg gastro-resistant tablet once daily for 4 weeks

Impaired Hepatic Function

Treatment for bleeding ulcer patients with severe liver impairment, following an initial bolus dose of 80 mg esomeprazole for infusion, a continuous intravenous infusion dose of 4 mg/hour for 71.5 hours may be sufficient.